DPP-1 inhibitor
DPP1 Inhibitors: First FDA Approval — China’s Fast-Follow Pipeline
Brensocatib earns FDA approval for NCFB, marking the first validated DPP1 inhibitor. We review the global and China pipelines, including HSK31858 and XH-S004.
DPP-1 inhibitor
Brensocatib earns FDA approval for NCFB, marking the first validated DPP1 inhibitor. We review the global and China pipelines, including HSK31858 and XH-S004.
FDA approvals
Insmed’s FDA approval of BRINSUPRI™ (brensocatib) for non-cystic fibrosis bronchiectasis marks a new era for neutrophil-targeted therapies. Originally discovered by AstraZeneca, brensocatib's success could reshape China’s respiratory drug innovation and investment landscape.